Compare AbCellera Biologics Inc (ABCL) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Chipotle Mexican Grill, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Chipotle Mexican Grill, Inc. trades at $33.31 (market cap $44.06B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 18.7× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | CMG | |
|---|---|---|
Market Cap | $2.35B | $44.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $56.41 |
52-Week Low | $2.78 | $28.17 |
Enterprise Value | $1.99B | $48.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Chipotle Mexican Grill (CMG) trades at $34.35, down 2.91% over 24 hours, with a bullish technical signal from moving averages and strong fundamentals including a 49.23% ROE and consistent earnings beats. Revenue grew to $11.93B in 2025, though net cash flow turned negative due to aggressive financing activities. Recent news highlights operational excellence and menu innovation as growth drivers amid competitive pressures.
Outlook remains positive with a $40.46 analyst consensus price target (70% buy ratings), but risks include cost inflation and softer comps. The stock offers upside from execution of expansion plans, yet investors face headwinds from consumer sentiment and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
